Biora Therapeutics, Inc. (PROG) |
|
0.8845 -0.032 (-3.47%)
|
05-09 00:00 |
|
Open: |
0.9005 |
Pre. Close: |
0.9163 |
|
High:
|
0.92 |
Low:
|
0.84 |
|
Volume:
|
2,779,613 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:23:53 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.07 One year: 1.25 |
| Support: |
Support1: 0.87 Support2: 0.83 |
| Resistance: |
Resistance1: 0.92 Resistance2: 1.07 |
| Pivot: |
0.88 |
| Moving Average: |
MA(5): 0.88 MA(20): 0.88
MA(100): 0.88 MA(250): 1.21  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 55.6 %D(3): 55.6 |
| RSI: |
RSI(14): 57.6 |
| 52-week: |
High: 3.88 Low: 0.56 |
| Average Vol(K): |
3-Month: 2,780 (K) 10-Days: 2,780 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PROG ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.92 - 0.93 |
0.93 - 0.93 |
|
Low:
|
0.83 - 0.83 |
0.83 - 0.84 |
|
Close:
|
0.88 - 0.89 |
0.89 - 0.89 |
|
Company Description |
|
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California. |
Headline News |
Thu, 02 Mar 2023
DelveInsight Evaluates a Robust Diabetes Pipeline as 200+ ... - PR Newswire
Thu, 23 Feb 2023
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist - Yahoo Finance
Thu, 16 Feb 2023
Biora Therapeutics Announces Improved Bioavailability Results for ... - GlobeNewswire
Thu, 19 Jan 2023
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress - Yahoo Finance
Wed, 11 Jan 2023
Biora Stock Skyrocketed Over 200% This Week; That’s Just the Start ... - TipRanks
Wed, 11 Jan 2023
What's Going On With Biora Therapeutics Stock? - Biora ... - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
164 (M) |
|
% Held by Insiders
|
1.3945e+008 (%) |
|
% Held by Institutions
|
9.1 (%) |
|
Shares Short
|
16,790 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.164e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
449.6 |
|
Return on Equity (ttm)
|
-56 |
|
Qtrly Rev. Growth
|
1.25e+006 |
|
Gross Profit (p.s.)
|
-0.12 |
|
Sales Per Share
|
0.45 |
|
EBITDA (p.s.)
|
-1.26 |
|
Qtrly Earnings Growth
|
-3.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-167 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
1.92 |
|
Price to Cash Flow
|
-0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.065e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
